266 related articles for article (PubMed ID: 31447303)
21. Might radiation therapy in addition to chemotherapy improve overall survival of patients with non-oligometastatic Stage IV non-small cell lung cancer?: Secondary analysis of two prospective studies.
Su S; Hu Y; Ouyang W; Ma Z; Li Q; Li H; Wang Y; Wang X; Li T; Li J; Chen M; Lu Y; Bai Y; He Z; Lu B
BMC Cancer; 2016 Nov; 16(1):908. PubMed ID: 27871270
[TBL] [Abstract][Full Text] [Related]
22. Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis.
Foster CC; Sher DJ; Rusthoven CG; Verma V; Spiotto MT; Weichselbaum RR; Koshy M
Radiat Oncol; 2019 Jan; 14(1):18. PubMed ID: 30691492
[TBL] [Abstract][Full Text] [Related]
23. Long-Term Outcomes of a Phase 2 Trial of Chemotherapy With Consolidative Radiation Therapy for Oligometastatic Non-Small Cell Lung Cancer.
Petty WJ; Urbanic JJ; Ahmed T; Hughes R; Levine B; Rusthoven K; Papagikos M; Ruiz JR; Lally BE; Chan M; Clark H; D'Agostino RB; Blackstock AW
Int J Radiat Oncol Biol Phys; 2018 Nov; 102(3):527-535. PubMed ID: 30003996
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of Local Consolidative Therapy for Oligometastatic Lung Adenocarcinoma Patients Harboring Epidermal Growth Factor Receptor Mutations.
Hu F; Xu J; Zhang B; Li C; Nie W; Gu P; Hu P; Wang H; Zhang Y; Shen Y; Wang S; Zhang X
Clin Lung Cancer; 2019 Jan; 20(1):e81-e90. PubMed ID: 30341018
[TBL] [Abstract][Full Text] [Related]
25. Consolidative Radiotherapy in Oligometastatic Lung Cancer: Patient Selection With a Prediction Nomogram.
Friedes C; Mai N; Hazell S; Fu W; Han P; Bowers M; Levy B; Forde PM; Voong R; Hales RK
Clin Lung Cancer; 2020 Nov; 21(6):e622-e632. PubMed ID: 32624411
[TBL] [Abstract][Full Text] [Related]
26. Outcome of radical local treatment of non-small cell lung cancer patients with synchronous oligometastases.
Kwint M; Walraven I; Burgers S; Hartemink K; Klomp H; Knegjens J; Verheij M; Belderbos J
Lung Cancer; 2017 Oct; 112():134-139. PubMed ID: 29191586
[TBL] [Abstract][Full Text] [Related]
27. Aggressive therapy for patients with non-small cell lung carcinoma and synchronous brain-only oligometastatic disease is associated with long-term survival.
Gray PJ; Mak RH; Yeap BY; Cryer SK; Pinnell NE; Christianson LW; Sher DJ; Arvold ND; Baldini EH; Chen AB; Kozono DE; Swanson SJ; Jackman DM; Alexander BM
Lung Cancer; 2014 Aug; 85(2):239-44. PubMed ID: 24974152
[TBL] [Abstract][Full Text] [Related]
28. Benchmarking Outcomes for Molecularly Characterized Synchronous Oligometastatic Non-Small-Cell Lung Cancer Reveals
De B; Farooqi AS; Mitchell KG; Ludmir EB; Lewis J; Rinsurongkawong W; Rinsurongkawong V; Lee JJ; Swisher SG; Gibbons DL; Zhang J; Le X; Elamin YY; Gomez DR; Ning MS; Lin SH; Liao Z; Chang JY; Vaporciyan AA; Heymach JV; Antonoff MB; Gandhi SJ
JCO Precis Oncol; 2023 Jan; 7():e2200540. PubMed ID: 36716413
[TBL] [Abstract][Full Text] [Related]
29. Metastasectomy for synchronous solitary non-small cell lung cancer metastases.
Tönnies M; Pfannschmidt J; Bauer TT; Kollmeier J; Tönnies S; Kaiser D
Ann Thorac Surg; 2014 Jul; 98(1):249-56. PubMed ID: 24820385
[TBL] [Abstract][Full Text] [Related]
30. Validation of the Disease-Specific GPA for Patients With 1 to 3 Synchronous Brain Metastases in Newly Diagnosed NSCLC.
Woody NM; Greer MD; Reddy CA; Videtic GMM; Chao ST; Murphy ES; Suh JH; Angelov L; Barnett GH; Vogelbaum MA; Stephans KL
Clin Lung Cancer; 2018 Jan; 19(1):e141-e147. PubMed ID: 28739316
[TBL] [Abstract][Full Text] [Related]
31. Synchronous Oligometastatic Lung Cancer Deserves a Dedicated Management.
Loi M; Mazzella A; Mansuet-Lupo A; Bobbio A; Canny E; Magdeleinat P; Régnard JF; Damotte D; Trédaniel J; Alifano M
Ann Thorac Surg; 2019 Apr; 107(4):1053-1059. PubMed ID: 30476480
[TBL] [Abstract][Full Text] [Related]
32. Management of Synchronous Extrathoracic Oligometastatic Non-Small Cell Lung Cancer.
Jones GD; Lengel HB; Hsu M; Tan KS; Caso R; Ghanie A; Connolly JG; Bains MS; Rusch VW; Huang J; Park BJ; Gomez DR; Jones DR; Rocco G
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33920810
[TBL] [Abstract][Full Text] [Related]
33. Additional local consolidative therapy has survival benefit over EGFR tyrosine kinase inhibitors alone in bone oligometastatic lung adenocarcinoma patients.
Hu F; Li C; Xu J; Guo J; Shen Y; Nie W; Zheng X; Wang L; Zhang H; Han B; Zhang X
Lung Cancer; 2019 Sep; 135():138-144. PubMed ID: 31446986
[TBL] [Abstract][Full Text] [Related]
34. Local Consolidative Therapy Versus Systemic Therapy Alone for Metastatic Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Wu Y; Verma V; Liang F; Lin Q; Zhou Z; Wang Z; Wang Y; Wang J; Chang JY
Int J Radiat Oncol Biol Phys; 2022 Nov; 114(4):635-644. PubMed ID: 35196537
[TBL] [Abstract][Full Text] [Related]
35. Recursive partitioning analysis of patients with oligometastatic non-small cell lung cancer: a retrospective study.
Zhang JT; Liu SY; Yan HH; Wu YL; Nie Q; Zhong WZ
BMC Cancer; 2019 Nov; 19(1):1051. PubMed ID: 31694572
[TBL] [Abstract][Full Text] [Related]
36. An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer.
Ashworth AB; Senan S; Palma DA; Riquet M; Ahn YC; Ricardi U; Congedo MT; Gomez DR; Wright GM; Melloni G; Milano MT; Sole CV; De Pas TM; Carter DL; Warner AJ; Rodrigues GB
Clin Lung Cancer; 2014 Sep; 15(5):346-55. PubMed ID: 24894943
[TBL] [Abstract][Full Text] [Related]
37. Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450).
De Ruysscher D; Wanders R; van Baardwijk A; Dingemans AM; Reymen B; Houben R; Bootsma G; Pitz C; van Eijsden L; Geraedts W; Baumert BG; Lambin P
J Thorac Oncol; 2012 Oct; 7(10):1547-55. PubMed ID: 22982655
[TBL] [Abstract][Full Text] [Related]
38. Propensity score-matched analysis of comprehensive local therapy for oligometastatic non-small cell lung cancer that did not progress after front-line chemotherapy.
Sheu T; Heymach JV; Swisher SG; Rao G; Weinberg JS; Mehran R; McAleer MF; Liao Z; Aloia TA; Gomez DR
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):850-7. PubMed ID: 25216859
[TBL] [Abstract][Full Text] [Related]
39. Local ablative treatment for synchronous single organ oligometastatic lung cancer-A propensity score analysis of 180 patients.
Frost N; Tessmer A; Schmittel A; van Laak V; Raspe M; Ruwwe-Glösenkamp C; Brunn M; Senger C; Böhmer D; Ochsenreither S; Temmesfeld-Wollbrück B; Furth C; Schmidt B; Neudecker J; Rückert JC; Suttorp N; Witzenrath M; Grohé C
Lung Cancer; 2018 Nov; 125():164-173. PubMed ID: 30429016
[TBL] [Abstract][Full Text] [Related]
40. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
